Literature DB >> 7552342

Cholesterol oxidation reduces Ca(2+)+MG (2+)-ATPase activity, interdigitation, and increases fluidity of brain synaptic plasma membranes.

W G Wood1, U Igbavboa, A M Rao, F Schroeder, N A Avdulov.   

Abstract

These experiments examined effects of cholesterol oxidation on Ca(2+)+Mg(2+)-ATPase activity, Na(+)+K(+)-ATPase activity, and membrane structure of brain synaptic plasma membranes (SPM). Cholesterol oxidase [E.C.1.1.3.6 from Brevibacterium sp.] was used to oxidize cholesterol. Two cholesterol pools were identified in synaptosomal membranes based on their accessibility to cholesterol oxidase. A rapidly oxidized cholesterol pool was observed with a 1t1/2 of 1.19 +/- 0.09 min and a second pool with a 2t1/2 of 38.30 +/- 4.16 min. Activity of Ca(2+)+Mg(2+)-ATPase was inhibited by low levels of cholesterol oxidation. Ten percent cholesterol oxidation, for example, resulted in approximately 35% percent inhibition of Ca(2+)+Mg(2+)-ATPase activity. After 13% cholesterol oxidation, further inhibition of Ca(2+)+Mg(2+)-ATPase activity was not observed. Activity of Na(+)+K(+)-ATPase was not affected by different levels of cholesterol oxidation (5%-40%). SPM interdigitation was significantly reduced and fluidity was significantly increased by cholesterol oxidation. The relationship observed between SPM interdigitation and Ca(2+)+Mg(2+)-ATPase activity was consistent with studies using model membranes [7]. Brain SPM function and structure were altered by relatively low levels of cholesterol oxidation and is a new approach to understanding cholesterol dynamics and neuronal function. The sensitivity of brain SPM to cholesterol oxidation may be important with respect to the proposed association between oxygen free radicals and certain neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552342     DOI: 10.1016/0006-8993(95)00347-s

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease.

Authors:  W G Wood; F Schroeder; N A Avdulov; S V Chochina; U Igbavboa
Journal:  Lipids       Date:  1999-03       Impact factor: 1.880

Review 2.  Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease.

Authors:  R J Mark; E M Blanc; M P Mattson
Journal:  Mol Neurobiol       Date:  1996-06       Impact factor: 5.590

3.  Expression of fatty acid binding proteins is altered in aged mouse brain.

Authors:  L Pu; U Igbavboa; W G Wood; J B Roths; A B Kier; F Spener; F Schroeder
Journal:  Mol Cell Biochem       Date:  1999-08       Impact factor: 3.396

4.  Alzheimer disease beta-amyloid activity mimics cholesterol oxidase.

Authors:  Luigi Puglielli; Avi L Friedlich; Kenneth D R Setchell; Seiichi Nagano; Carlos Opazo; Robert A Cherny; Kevin J Barnham; John D Wade; Simon Melov; Dora M Kovacs; Ashley I Bush
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

5.  Regulation of transverse tubule ecto-ATPase activity in chicken skeletal muscle.

Authors:  A Megías; M M Martínez-Senac; J Delgado; A Saborido
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

Review 6.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

7.  Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes.

Authors:  U Igbavboa; G Y Sun; G A Weisman; Yan He; W G Wood
Journal:  Neuroscience       Date:  2009-05-03       Impact factor: 3.590

8.  Extracellular calcium reduction strongly increases the lytic capacity of pneumolysin from streptococcus pneumoniae in brain tissue.

Authors:  Carolin Wippel; Christina Förtsch; Sabrina Hupp; Elke Maier; Roland Benz; Jiangtao Ma; Timothy J Mitchell; Asparouh I Iliev
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.